NIOX Competitors and Similar CompaniesClear all
Affimed N.V.'s competitors and similar companies include Durect.
 Affimed N.V. Affimed is a NASDAQ-listed clinical-stage biopharmaceutical company focused on discovering and developing targeted immuno-oncology therapies. |  Durect DURECT is a specialty pharmaceutical company developing innovative drugs for pain and chronic diseases. | |
Type | Type Public | Type Public |
Tags | ||
Locations | Locations Heidelberg, DE HQ | Locations Cupertino, US HQ |
Employees | Employees 76 | Employees 902% increase |
Valuation ($) | Valuation ($) 52.5 m | Valuation ($) 45.3 m |
Financial | ||
Revenue (est.) | Revenue (est.) €8.3m (FY, 2023) | Revenue (est.) $2m (FY, 2024) |
Cost of goods | Cost of goods N/A | Cost of goods $78k (FY, 2024) |
Gross profit | Gross profit €13m (FY, 2023) | Gross profit $2m (FY, 2024) |
Net income | Net income (€105.9m) (FY, 2023) | Net income ($8.3m) (FY, 2024) |
For sources of this data, please see the company profile
View Company Profiles
Durect
HQ
Cupertino, US
Employees
90↑ 2% increase
DURECT is a specialty pharmaceutical company developing innovative drugs for pain and chronic diseases.
View company